GleamWall
中文EN

JSPR Jasper Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1788028 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-73.0%
TTM EPS YoY184.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-153.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets14.2%
Debt / equity—
Current ratio10.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.31x
Accruals ratio-106.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$8.00M———————
Cost of revenue$4.32M$3.58M$3.62M$6.76M$9.35M$15.77M$9.76M$13.17M
Gross profit$3.68M———————
R&D expense$8.33M$5.13M$5.81M$11.36M$14.39M$21.20M$16.16M$19.77M
SG&A expense$6.36M$4.07M$5.14M$4.48M$4.78M$5.88M$5.64M$5.51M
Operating income-$144.17M-$9.21M-$10.95M-$15.84M-$19.17M-$27.08M-$21.80M-$25.29M
Net income-$144.46M-$2.76M-$1.17M-$9.10M-$18.74M-$26.72M-$21.24M-$24.32M
EBITDA-$144.16M$11.79M-$10.93M-$15.55M-$18.97M-$26.78M-$21.52M-$25.04M
EPS (basic)-10.19-0.10-0.04—-32.08-1.74-1.41—
EPS (diluted)-10.19-0.10-0.04—-32.08-1.74-1.41—
Weighted avg. shares (diluted)1.08M28.70M28.67M—584,05615.33M15.02M—
Balance sheet
Cash & equivalents$135.35M$7.31M$14.14M$28.69M$51.32M$39.93M$49.22M$72.05M
Receivables$8.00M———————
Current assets$147.27M$11.57M$20.29M$34.65M$54.56M$42.97M$53.17M$75.81M
PP&E, net$57,000$60,000$81,000$102,000$1.10M$1.33M$1.60M$1.88M
Total assets$147.42M$11.80M$21.18M$35.78M$57.47M$46.47M$57.60M$79.90M
Current liabilities$13.91M$7.84M$9.00M$13.20M$21.04M$20.50M$12.33M$15.24M
Total liabilities$20.89M$10.39M$17.78M$31.63M$45.90M$22.96M$15.35M$18.23M
Shareholders' equity-$140.25M$1.41M$3.40M$4.15M$11.57M$23.50M$42.24M$61.67M
Shares outstanding1.11M28.08M28.00M933,24227.98M16.22M15.02M15.02M
Cash flow statement
Operating cash flow-$5.50M-$6.92M-$14.55M-$21.87M-$17.00M-$15.45M-$22.84M-$21.13M
Capital expenditure————$0———
Free cash flow————-$17.00M———
Investing cash flow$7.70M——$0$0$1,000$4,000-$76,000
Financing cash flow$125.83M——-$340,000$28.39M——$345,000
Depreciation & amortization$16,000$21.00M$21,000$290,000$200,000$300,000$279,000$245,000
Stock-based compensation$1.22M$764,000$423,000$1.66M$1.42M$1.82M$1.81M$1.97M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.